Vilon Dosage: Immune Research Protocol

Read this first

Dosage and protocol figures on this page are reproduced only from the matching PeptideDosages.com protocol. The 3 ml table is arithmetic based on those source amounts and the listed vial sizes. Educational research only — not instructions or medical advice.

Dosage chart

The dosage amounts and schedules below come only from PeptideDosages.com. Syringe-unit figures are mathematical conversions of those source amounts using exactly 3 ml of bacteriostatic water. Educational reference only — not instructions or medical advice.

Vilon · 20 mg Vial

Vilon is dosed at 67 mcg–667 mcg daily via subcutaneous injection in educational protocols.

Typical range: 67–670 mcg once daily for 5 consecutive days per cycle.

Standard / Gradual Approach

Phase / Cycle	Daily Dose (mcg)
Cycle 1, Day 1	67 mcg (0.067 mg)
Cycle 1, Day 2	133 mcg (0.133 mg)
Cycle 1, Day 3	200 mcg (0.20 mg)
Cycle 1, Day 4	267 mcg (0.267 mg)
Cycle 1, Day 5	333 mcg (0.33 mg)
Cycle 2+ (Days 1–5)	333–667 mcg (0.33–0.67 mg)

3 ml conversion

Select vial strength

20 mg + 3 ml = 6.67 mg/ml. Choose your vial strength to update the units below.

Source dose	U-100 syringe
67 mcg	1.0 units
133 mcg	2.0 units
200 mcg	3.0 units
267 mcg	4.0 units
333 mcg	5.0 units
0.33 mg	4.9 units
667 mcg	10 units
0.67 mg	10 units

Source chart on peptidedosages.com

Other immune compounds

VIP28-amino-acid neuropeptide AdamaxCyclic Semax analogue (cyclo-prolylglycine related)ChonlutenSynthetic tripeptide bioregulator (bronchial/lung sequence)KPVα-MSH C-terminal tripeptide LL-3737-amino-acid cathelicidin antimicrobial peptide ThymalinThymic peptide extract preparation

All research protocols

Vilon: research background

What the compound is

Vilon is a synthetic dipeptide, meaning it is made of two amino acids linked together. Its specific amino acid sequence is Lys-Glu (Lysine-Glutamic acid) (PMID 12209581, PMID 37042594, PMID 12360356, PMID 11140587, PMID 12420071, PMID 25826983).

How it is thought to work

Vilon, along with other short peptide bioregulators, is believed to induce selective heterochromatinization and deheterochromatinization (remodeling of facultative heterochromatin) of chromosome regions in lymphocytes from individuals aged 75-88 years. This process involves the unrolling or decondensation of total heterochromatin and satellite stalks of acrocentric chromosomes, which activates the synthetic processes of ribosomal genes (PMID 37042594). These short peptides are also known to regulate gene expression and protein synthesis (PMID 25826983). Studies using DNA-microarray technology in mice found that Vilon alone changed the expression of 36 clones (genes or DNA sequences), activating 157 clones and inhibiting 23 clones in the heart (PMID 12360356).

What laboratory and animal studies report

In female CBA mice, subcutaneous administration of Vilon starting at 6 months of age increased physical activity and endurance, decreased body temperature, prolonged lifespan, and prevented the development of spontaneous neoplasms (PMID 11140587). In aged rats, oral administration of Vilon for one month improved transport characteristics of the small intestine, specifically enhancing passive glucose accumulation in the serous fluid of the distal small intestine and stimulating active glucose accumulation in the serous sac of the medial small intestine (PMID 12420071). Vilon also demonstrated an 'oncomodulating action' in mice with transplanted Lewis lung carcinoma, increasing the survival of the mice when injected at 1 mg/kg doses (PMID 14743610). However, a different study in female FVB/N HER-2/neu transgenic mice reported that Vilon treatment (1 microg/mouse for 5 consecutive days monthly) produced significant negative effects, including an increased incidence of mammary cancer, a shorter mean latent period of tumors, and an increased cumulative number of tumors, compared to control animals. While Vilon partially reduced HER-2/neu mRNA expression in mammary tumors, it remained significantly higher than in Epitalon-treated animals (PMID 12209581). In organotypic spleen tissue cultures from young and old rats, Vilon stimulated apoptosis (programmed cell death) (PMID 14743610).

Open questions and limitations

Although Vilon has shown some positive effects in geroprotection and cancer modulation in animal models, its use in combination with cytostatic drugs like cyclophosphan resulted in decreased survival in mice, suggesting they should not be used synchronously (PMID 14743610). Furthermore, Vilon's effect on mammary cancer development in HER-2/neu transgenic mice showed concerning negative outcomes, including increased tumor incidence (PMID 12209581). These contrasting findings in different cancer models highlight the complexity of Vilon's effects. One abstract uses 'ViLoN' as an algorithm for data integration in patient stratification, which is unrelated to the Lys-Glu peptide (PMID 36395816). There are no human studies described regarding the Lys-Glu peptide Vilon's effects.

Studies cited in this section

ViLoN-a multi-layer network approach to data integration demonstrated for patient stratification. — Nucleic acids research, 2023 (PMID 36395816)
Inhibitory effect of the peptide epitalon on the development of spontaneous mammary tumors in HER-2/neu transgenic mice. — International journal of cancer, 2002 (PMID 12209581)
EPIGENETIC MODIFICATION UNDER THE INFLUENCE OF PEPTIDE BIOREGULATORS ON THE "OLD" CHROMATIN. — Georgian medical news, 2023 (PMID 37042594)
Studies of the effects of Vilon and Epithalon on gene expression in mouse heart using DNA-microarray technology. — Bulletin of experimental biology and medicine, 2002 (PMID 12360356)
Effect of vilon on biological age and lifespan in mice. — Bulletin of experimental biology and medicine, 2000 (PMID 11140587)
Effect of Vilon and Epithalon on glucose and glycine absorption in various regions of small intestine in aged rats. — Bulletin of experimental biology and medicine, 2002 (PMID 12420071)
[Combined effect of vilon and cyclophosphane on tumor transplants and lymphoid tissue explants in mice and rats of various age]. — Advances in gerontology = Uspekhi gerontologii, 2003 (PMID 14743610)
[Peptides and CCL11 and HMGB1 as molecular markers of aging: literature review and own data]. — Advances in gerontology = Uspekhi gerontologii, 2014 (PMID 25826983)

Summarised from the PubMed abstracts listed above. Educational reference only — not medical advice or instructions.

Nearby in the protocol A–Z

Peptide Intel Hub is an independent publication and has no affiliation, ownership or commercial relationship with the suppliers listed. We sell nothing and take no payments — links are editorial references only.

Vilon dosage protocol